CROI 2024 Program Guide

Poster Sessions by Category

P-K2 P-K3 P-K4

Cardiovascular Disease Trends and Risk Factor Modification (Tuesday) Hypertension: Risk Factors and Interventions (Tuesday)

Heart Failure and Microvascular Health (Wednesday)

L. Other Complications of HIV Infection and Antiretroviral Therapy in Adults P-L1 GLP-1 Receptor Agonists for Weight Loss in HIV (Monday) P-L2 Metabolic Outcomes (Wednesday) P-L3 Weight Gain and Metabolism (Monday) P-L4 Antiretroviral Therapy: Immunologic Effects (Tuesday) P-L5 Sex Differences in Comorbidities and Inflammation (Tuesday) P-L6 Pulmonary Outcomes (Monday) P-L7 Renal Outcomes (Tuesday) P-L8 Mental Health Outcomes (Wednesday) P-L9 Aging and Frailty (Wednesday) M. Clinical Manifestations and Outcomes of SARS-CoV-2, Including Long COVID, and Mpox Infections P-M1 Post-Acute COVID-19 Syndrome: Predictors, Associations, and Clinical Manifestations (Monday) P-M2 Factors Affecting Outcome of Acute COVID-19 (Tuesday) N. Tuberculosis and Other Opportunistic Infections, Including the Impact of HIV or SARS-CoV-2 in Adults P-N1 Pharmacologic and Other Programmatic Insights in Tuberculosis and Cryptococcal Meningitis (Monday) P-N2 Issues in Tuberculosis Preventive Therapy (Monday) P-N3 Immunologic Risk and Immune Activation in Tuberculosis and Other Opportunistic Infections (Monday) P-N4 Mortality Risk in Cryptococcal Meningitis and Other Invasive Mycoses (Tuesday) P-N5 Diagnostic Testing and Novel Biomarkers for Invasive Mycoses and Tuberculosis (Wednesday) O. Maternal and Fetal HIV, SARS-CoV-2, and Mpox Virus P-O1 Preventing HIV in Pregnancy and Breastfeeding (Wednesday) P-O2 Improving Maternal Outcomes on Antiretroviral Therapy (Wednesday) P-O3 Chronic Diseases, Pregnancy, and HIV (Tuesday) P-O4 Maternal Mental Health and HIV (Monday) P-O5 Understanding Breastmilk, HIV, and Antiretrovirals (Monday) P-O6 HIV and Birth Outcomes (Tuesday) P. Childhood and Adolescent HIV, SARS-CoV-2, or Mpox Virus P-P1 Health and Outcomes of Children Exposed to Antiretrovirals in Utero (Tuesday) P-P2 Pharmacokinetics, Dosing, and Safety of Antiretrovirals for Infants, Children, and Adolescents (Tuesday) P-P3 Exploring the Pediatric Reservoir (Monday) P-P4 Infants With HIV Infection: Diagnosis, Mortality, Morbidity, and Treatment Response (Tuesday) P-P5 Comorbidities and Complications in Children and Adolescents with HIV Infection (Wednesday) P-P6 Pediatric Antiretroviral Therapy Optimization: Dolutegravir in Action (Tuesday) P-P7 Intervention to Improve Testing and Care for Children and Adolescents (Wednesday)

Poster Sessions by Category

CROI 2024 182